<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Carotid artery stenting (CAS) was approved by the government and reimbursement was started in 2008 in Japan, probably the last country in the world </plain></SENT>
<SENT sid="1" pm="."><plain>CASCARD is a retrospective registry study performed by cardiologists to assess initial results of CAS in Japan </plain></SENT>
<SENT sid="2" pm="."><plain>CAS was indicated for patients with at least one high risk factor for carotid endarterectomy and with &gt;50 % stenosis in symptomatic or &gt;80 % stenosis in asymptomatic patients </plain></SENT>
<SENT sid="3" pm="."><plain>Primary endpoint was major adverse events (MAE) including <z:hpo ids='HP_0011420'>death</z:hpo>, <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> and any <z:hpo ids='HP_0001297'>stroke</z:hpo> at 30 days </plain></SENT>
<SENT sid="4" pm="."><plain>Between April 2008 and March 2010, a total of 704 cases were enrolled from 55 centers </plain></SENT>
<SENT sid="5" pm="."><plain>The study population with an average age of 74 ± 8 years included 62 % asymptomatic patients, with 23 % of cases with contralateral carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> or significant stenoses </plain></SENT>
<SENT sid="6" pm="."><plain>Angioguard filter wire was exclusively used as a primary protection device and successfully passed the lesion in 701 cases (99.6 %) </plain></SENT>
<SENT sid="7" pm="."><plain>Precise stent was implanted successfully in <z:hpo ids='HP_0000001'>all</z:hpo> cases </plain></SENT>
<SENT sid="8" pm="."><plain>MAE at 30 days was 3.7:0.3 % <z:hpo ids='HP_0011420'>death</z:hpo>, 0 % <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, and 3.4 % <z:hpo ids='HP_0001297'>stroke</z:hpo> (0.4 % major ipsilateral <z:hpo ids='HP_0001297'>stroke</z:hpo>) </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0011420'>Death</z:hpo> or any <z:hpo ids='HP_0001297'>stroke</z:hpo> rate at 30 days was 2.7 % in asymptomatic and 5.5 % in symptomatic patients </plain></SENT>
<SENT sid="10" pm="."><plain>The CASCARD study showed that the initial results of CAS in Japan are acceptable for both symptomatic and asymptomatic cases </plain></SENT>
</text></document>